{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:50:21Z","timestamp":1761490221392},"reference-count":19,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,1]]},"abstract":" PURPOSE: An approach to providing informed consent to breast cancer survivors considering hormone replacement therapy (HRT) is offered. <\/jats:p> METHODS: Current information on HRT, breast cancer, and chronic disease prevention is reviewed in the context of risks faced by women with resected breast cancer. <\/jats:p> RESULTS: Breast cancer patients, unwilling to trade symptom reduction for even a small increase in recurrence risk, are at substantially increased risk of death from breast cancer relative to other causes. Observational studies suggest that long-term HRT increases breast cancer development. The influence of HRT on the growth of established breast cancer has not been determined; however, estrogen reduction (oophorectomy) significantly reduces recurrence in premenopausal women, and current evidence cannot exclude a risk that HRT increases recurrence to the same degree. The following issues are of particular relevance to breast cancer survivors: HRT reduces mammographic sensitivity, increases thromboembolic events, and increases endometrial cancer risk. Although benefit for HRT is commonly inferred from observational studies, randomized trials of HRT on all-cause mortality have not been completed. For coronary heart disease prevention, an array of strategies independent of HRT are available, with some (tamoxifen, selective estrogen receptor modifiers [SERMs], diet, and exercise) likely to favorably influence breast cancer risk; for osteoporosis prevention, an array of strategies also are available, with some (bisphosphonates, tamoxifen, SERMs, and exercise) likely to favorably influence breast cancer risk. <\/jats:p> CONCLUSION: Current data preclude the generation of evidence-based guidelines for HRT use in breast cancer survivors, and clinical trials in this setting should be supported. However, given available therapeutic alternatives for menopausal symptom management and chronic disease prevention, breast cancer survivors should be offered HRT only with caution and with their full participation in the decision-making process. <\/jats:p>","DOI":"10.1200\/jco.1999.17.1.130","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:52:05Z","timestamp":1487919125000},"page":"130-130","source":"Crossref","is-referenced-by-count":32,"title":["Elements of Informed Consent for Hormone Replacement Therapy in Patients With Diagnosed Breast Cancer"],"prefix":"10.1200","volume":"17","author":[{"given":"Rowan T.","family":"Chlebowski","sequence":"first","affiliation":[{"name":"From the University of California Los Angeles School of Medicine, Harbor-UCLA (University of California Los Angeles) Medical Center, Torrance, California; and Fred Hutchinson Comprehensive Cancer Center, Seattle, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"McTiernan","sequence":"additional","affiliation":[{"name":"From the University of California Los Angeles School of Medicine, Harbor-UCLA (University of California Los Angeles) Medical Center, Torrance, California; and Fred Hutchinson Comprehensive Cancer Center, Seattle, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R10-0130","unstructured":"Nayfield S, Ford L, Parsons J, et al: Hormone replacement therapy (HRT) in breast cancer (BC): Physician practices. Proc Am Soc Clin Oncol 13:471,1994, (abstr)"},{"key":"R20-0130","unstructured":"Lindley CM, Vasa SP, Swayer WT, et al: Eliciting preferences for adjuvant therapy in patients with early stage breast cancer: Tradeoffs between treatment, cure, and survival. Proc Am Soc Clin Oncol 14:149,1995, (abstr)"},{"key":"R23-0130","unstructured":"Pritchard KI, Llewellyn-Thomas H, Lewis J, et al: The use of a probability trade-off task (PT-OT) to assess maximal acceptable increment in risk of breast cancer recurrence (MAIRR) in order to estimate sample size for a randomized clinical trial of hormone replacement therapy (HRT) in women with a previous diagnosis of breast cancer. Proc Am Soc Clin Oncol 15:213,1996, (abstr)"},{"key":"R51-0130","doi-asserted-by":"crossref","unstructured":"Shi YE, Lui YE, Lippman ME, et al: Progestins and antiprogestins in mammary tumor growth and metastasis. Hum Reprod 9:162,1994-173, (suppl 1)","DOI":"10.1093\/humrep\/9.suppl_1.162"},{"key":"R64-0130","unstructured":"Decker D, Cox T, Burdakin J, et al: Hormone replacement therapy (HRT) in breast cancer survivors. Proc Am Soc Clin Oncol 15:209,1996, (abstr)"},{"key":"R66-0130","unstructured":"Bluming AZ, Waisman JR, Dosik GA, et al: Hormone replacement therapy (HRT) in women with previously treated primary breast cancer, update IV. Proc Am Soc Clin Oncol 17:496,1998, (abstr)"},{"key":"R70-0130","unstructured":"Marsden J, Baum M, Whitehead MI, et al: A randomized trial of HRT in women with a history of breast cancer: A feasibility study. Acta Obstet Gynecol Scand 76:22,1997, (suppl 167)"},{"key":"R117-0130","unstructured":"Law M, Loprinzi CL, Kugler J, et al: Double-blind crossover trial of Replens versus KY jelly for treating vaginal dryness and dyspareunia in breast cancer survivors. Proc Am Soc Clin Oncol 15:241,1996, (abstr)"},{"key":"R120-0130","unstructured":"Pandoza KJ, Morrow GR, Flynn PJ, et al: Oral clonidine in post-menopausal breast cancer patients with tamoxifen induced hot flashes: A URCC CCOP Study. Proc Am Soc Clin Oncol 16:170,1997, (abstr)"},{"key":"R127-0130","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.495"},{"key":"R128-0130","unstructured":"Wang C, Kurzer MS: Effects of isoflavones flavinoids and lignoins on proliferation of estrogen-dependent and independent human breast cancer cells. Proc Am Assoc Cancer Res 37:277,1996, (abstr)"},{"key":"R138-0130","doi-asserted-by":"crossref","unstructured":"Powles TJ, McCloskey E, Patterson AHG, et al: Oral clodronate will reduce the loss of bone mineral density in women with primary breast cancer. Proc Am Soc Clin Oncol 16:461,1997, (abstr)","DOI":"10.1016\/S0959-8049(97)84751-X"},{"key":"R140-0130","unstructured":"Diel IJ, Solomayer EF, Goerner R, et al: Adjuvant treatment of breast cancer patients with the bisphosphonate clodronate reduces incidence and number of bone and non-bone metastases. Proc Am Soc Clin Oncol 16:461,1997, (abstr)"},{"key":"R141-0130","unstructured":"Paterson AHG, McCloskey EV, Ashley S, et al: Reduction of skeletal morbidity and prevention of bone metastases with oral clodronate in women with recurrent breast cancer in the absence of skeletal metastases. Proc Am Soc Clin Oncol 15:81,1996, (abstr)"},{"key":"R143-0130","unstructured":"Lipton A, Hershey PA, Theriault R, et al: Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy by monthly 90 mg pamidronate infusions. Proc Am Soc Clin Oncol 16:531,1997, (abstr)"},{"key":"R147-0130","unstructured":"Fisher B, Digman J, DeCillis A, et al: The worth of chemotherapy and tamoxifen (TAM) over TAM alone in node negative patients with estrogen receptor (ER) positive invasive breast cancer (BC): First results from NSABP B-20. Proc Am Soc Clin Oncol 16:1,1997, (abstr)"},{"key":"R153-0130","unstructured":"Bradbeer J, Stroup GB, Hoffman S: Idoxifene prevents bone loss and reduces serum cholesterol in the ovariectomized rat. J Bone Miner Res 11:236,1996-241, (suppl 1)"},{"key":"R167-0130","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.7.605"},{"key":"R179-0130","unstructured":"Pierce JP, Parker B, Wright F: A feasability study for a randomized controlled trial of a plant-based diet on breast cancer recurrence. Proc Am Soc Clin Oncol 14:160,1995, (abstr)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.1.130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:42:10Z","timestamp":1653514930000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.1.130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["10.1200\/JCO.1999.17.1.130"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.1.130","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}